Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43